



# Rapid Dose Therapeutics Commences Clinical Research Trial with GI Research Institute and University of British Columbia

BURLINGTON, ON, Aug. 20, 2019 /CNW/ - **Rapid Dose Therapeutics Corp.** (**CSE: DOSE**), ("RDT") announced today the commencement of a clinical research trial with the GI Research Institute ("GIRI") and the University of British Columbia ("UBC") under the direction of Dr. Brian L. Bressler, MD, as Principal Investigator. The objective of this study is to evaluate the effectiveness of providing daily doses of QuickStrip™ Vitamin B12 oral thin film strips to Inflammatory Bowel Disease ("IBD") patients who are vitamin B12 deficient.

IBD is a chronic gastrointestinal condition that afflicts approximately 270,000 Canadians and more than 5 million people worldwide and causes inflammation that can lead to ulceration of the intestinal tract that often results in poor absorption of essential nutrients and vitamins. Vitamin B12 deficiency is generally treated with injections or orally ingested pills. Injections may be unpleasant for some patients while others may have difficulty with swallowing pills. Rapidly dissolving QuickStrip™ B12 oral thin film strips may provide an effective and convenient solution to individuals needing daily B12 supplementation.

"We are delighted to engage in this clinical study, initiated and led by Dr. Brian Bressler, and the GIRI team of researchers, as Dr. Bressler is one of Canada's foremost leaders in the area of gastroenterology and the treatment of IBD," said Dr. Rina Carlini, VP, Research & Innovation of RDT.

"We are excited to be involved in this study to learn how this new delivery of vitamin B12 can help replace this essential nutrient in patients with IBD in an efficient and convenient way," said Dr. Bressler.

RDT's proprietary QuickStrip™ technology is an oral dispersible thin film drug delivery system that rapidly delivers active medicinal agents directly to the bloodstream via transfer through the sublingual or buccal mucosa (mouth), bypassing metabolism of the active agent in the gastrointestinal tract.

GIRI, located in Vancouver, BC, is affiliated with Pacific Gastroenterology Associates and supports clinical research and helps advance education in gastrointestinal disease.

## About Rapid Dose Therapeutics

Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development in the healthcare industry, including nutraceutical, pharmaceutical and cannabis sectors. Within the cannabis sector, RDT provides a turn-key Managed Strip Service Program which enables RDT's QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT's service-based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. Rapid Dose Therapeutics is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs.

For more information, visit: [www.rapid-dose.com](http://www.rapid-dose.com)

## Social Media

[RapidDoseTherapeutics.linkedin](#)

[RapidDoseTherapeutics.twitter](#)

[RapidDoseTherapeutics.facebook](#)

[QuickStrip.instagram](#)

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:** *Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to them. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.*



QuickStrip™ Anytime, Anywhere™ (CNW Group/Rapid Dose Therapeutics Corp.)

View original content to download multimedia:

<http://www.prnewswire.com/news-releases/rapid-dose-therapeutics-commences-clinical-research-trial-with-gi-research-institute-and-university-of-british-columbia-3>

SOURCE Rapid Dose Therapeutics Corp.

View original content to download multimedia: <http://www.newswire.ca/en/releases/archive/August2019/20/c5272.html>

%SEDAR: 00028805E

**For further information:** For inquiries please contact: Mark Upsdell, CEO, Rapid Dose Therapeutics, [mupsdell@rapid-dose.com](mailto:mupsdell@rapid-dose.com), Office (416) 477-1052; Ali Mahdavi, Managing Director, Spinnaker Capital Markets Inc., [am@spinnakercmi.com](mailto:am@spinnakercmi.com), Office (416) 962-3300

CO: Rapid Dose Therapeutics Corp.

CNW 07:00e 20-AUG-19